Navigation Links
Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy
Date:3/20/2009

nts receiving moderately emetogenic chemotherapies. A single intravenous dose of palonosetron (0.25 mg) provides better protection from CINV than first-generation 5-HT3 receptor antagonists throughout a 5-day post-chemotherapy period*. This means that a single administration of palonosetron also grants protection during the delayed phase of CINV*.

Palonosetron 0.075 mg IV is also approved by FDA as a single intravenous dose administered immediately before the induction of anaesthesia for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

Palonosetron is contraindicated in patients known to have hypersensitivity to the drug or any of its components. The most commonly reported adverse reactions (incidence greater than or equal to 2%) in CINV trials with palonosetron were headache (9%) and constipation (5%), and they were similar to the comparators. In PONV trials, the most commonly reported adverse reactions were QT prolongation (5%), bradycardia (4%), headache (3%), and constipation (2%), similar to placebo.

Palonosetron has been developed by Helsinn Healthcare SA of Switzerland and today it is marketed as Aloxi(R), Onicit(R), and Paloxi(R). Palonosetron, marketed as Aloxi(r), is the leading brand in the USA within the CINV Day of Chemo segment, and it is steadily growing in the European markets. Its approval in Japan is expected during 2009.

For more information about palonosetron, please visit the website: http://www.aloxi.com

About Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and subsidiaries in Ireland and USA. Helsinn is the worldwide licensor of palonosetron.

Helsinn's unique business model is focused on the licensing of pharmaceuticals and medical devices in therapeutic niche areas. The Gr
'/>"/>

SOURCE Helsinn Healthcare SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
2. Imagenetix Reports Results of Offer to Extend Warrants
3. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
4. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
7. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
8. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
9. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
10. Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
11. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)...  BioNano Genomics, Inc., the leader in genome mapping, ... chief commercial officer. Salyer has more than 20 years ... life sciences. At BioNano, Salyer will oversee the commercialization ... to assemble a comprehensive view of complex genomes to ... institutions located in the United States ...
(Date:3/26/2015)... 26, 2015 Neogen Corporation (NASDAQ: NEOG ... third quarter of fiscal 2015, which ended Feb. 28, ... year,s $6,575,000. Earnings per share in the current quarter ... year-to-date net income increased 17% over prior year to ... $0.56 per share, for the same period a year ...
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will ... Align Technology, on “ Conducting Postmarket Registries - Rationale ... Conference and Exhibition on April 25th through April 28th ... poster presentation, Ale Gicqueau and Victor Chen will discuss ... the requirements and resources to conduct the registry, as ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3
... Wis. Information-technology businesses are taking apart their ... Fusion 2005 CEO-CIO Symposium on Wednesday just around ... Wisconsin offered their opinions on how the state and ... the year progresses. , Restructuring and rebuilding ,According ...
... education products in Wisconsin Rapids, has sold Generation21 Learning ... ,Generation21 lost $4.6 million before taxes on $2.6 million ... looked for strategic alternatives over the past few years ... option. , ,The company will record a $600,000 gain ...
... Wis. There may no yellow tape or chalk ... of computer crimes if they want remedies, said a lawyer ... on Wednesday. , ,Daniel Vaccaro, a partner with Michael ... been compromised by Internet fraudsters or disgruntled employees can benefit ...
Cached Biology Technology:Restructuring is a watchword for IT in 2005 2Restructuring is a watchword for IT in 2005 3After a successful attack on your computer systems, then what? 2After a successful attack on your computer systems, then what? 3
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/16/2015)... 2015 Between 16 and ... groundbreaking innovations in biometric identification at the CeBIT ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) ... well at the forefront: the company,s all new ... Germany . BiometricGate is the ...
(Date:3/11/2015)... and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has announced ... Product, Application & By Geography - Global Forecast & ... This report predicts that the access control ... with an estimated CAGR of 10.6%. The ... as contact cards & readers, contactless cards & readers, ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... of its kind, researchers at Queens College and Mount ... status (SES) and maternal gestational diabetes together may cause ... (ADHD) in six year olds. The data are published ... Pediatrics and Adolescent Medicine , one of the JAMA/Archives ...
... Group, Inc. (Pinksheets: EVRM) would like to issue the ... foremost, I want to thank our supporters; it has ... Evermedia Group, advancing the interests of wholly owned subsidiaries: ... have been fortunate to work with many outstanding professionals ...
... Chimpanzees, orangutans, gorillas and bonobos make more sophisticated decisions ... success, based on what they know and the likelihood to ... Daniel Haun, published on December 21 in the online journal ... human decision-making as well. The authors of the ...
Cached Biology News:Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2The Evermedia Group 2011 Year in Review 2The Evermedia Group 2011 Year in Review 3The Evermedia Group 2011 Year in Review 4
Normal human AB serum, pooled...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
XBP1 Antibody...
Recombinant Mouse MMP-9, CF...
Biology Products: